IMUX Overview
Upcoming Projects (IMUX)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (IMUX)
-
A look at IMU-935, a RORγt inverse agonist for the treatment of moderate-severe psoriasis
Ticker: IMUX
Executed On: Mar 14, 2022 at 03:00 PM EDT -
A Second View: Examining IMU-838 (vidofludimus calcium) as a potential therapy for moderate-severe ulcerative colitis ahead of the phase 2 readout of the CALDOSE-1 trial
Ticker: IMUX
Executed On: Feb 28, 2022 at 08:00 AM EST -
A look at IMU-838 (vidofludimus calcium) as a potential therapy for moderate-severe ulcerative colitis ahead of the phase 2 readout of the CALDOSE-1 trial.
Ticker: IMUX
Executed On: Feb 22, 2022 at 09:15 AM EST
Upcoming & Overdue Catalysts (IMUX)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (IMUX)
-
Top-line Data Reported from Immunic's (IMUX) Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis
Ticker: IMUX
Occurred on: Aug 02, 2020
Strategic Initiatives (IMUX)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
